Tracey McCain
Compliance Officer chez BLUEPRINT MEDICINES CORPORATION
Fortune : 7 M $ au 30/06/2024
Profil
Tracey L.
McCain is currently serving as an Independent Director at Kiniksa Pharmaceuticals Ltd.
since 2018, as a Director at Kiniksa Pharmaceuticals International Plc since 2024, and as the Secretary, Chief Legal & Compliance Officer at Blueprint Medicines Corp.
since 2016.
Previously, McCain held the position of Independent Director at ImmunoGen, Inc. from 2021 to 2024 and served as the General Counsel at Genzyme Corp.
from 1997 to 2016.
McCain also worked as an Associate at Palmer & Dodge LLP and as the Senior Vice President & Head-Legal at Genzyme Therapeutics Ltd.
in 2016.
McCain completed an undergraduate degree at the University of Pennsylvania in 1989 and obtained a graduate degree from Columbia Law School in 1992.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 07/03/2024 | 60 498 ( 0,10% ) | 7 M $ | 30/06/2024 | |
0,02% | 06/06/2024 | 9 373 ( 0,02% ) | 174 994 $ | 30/06/2024 |
Postes actifs de Tracey McCain
| Sociétés | Poste | Début |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Compliance Officer | 06/09/2016 |
| KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC | Directeur/Membre du Conseil | 01/02/2018 |
Anciens postes connus de Tracey McCain
| Sociétés | Poste | Fin |
|---|---|---|
| IMMUNOGEN, INC. | Directeur/Membre du Conseil | 12/02/2024 |
Genzyme Therapeutics Ltd.
 Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Conseiller Juridique Général | 02/09/2016 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Conseiller Juridique Général | 01/09/2016 |
| Palmer & Dodge LLP | Corporate Officer/Principal | - |
Formation de Tracey McCain
| University of Pennsylvania | Undergraduate Degree |
| Columbia Law School | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| Entreprise privées | 5 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
| Palmer & Dodge LLP | Commercial Services |
Kiniksa Pharmaceuticals Ltd.
 Kiniksa Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Kiniksa Pharmaceuticals International Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA. | Health Technology |
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA. | Health Technology |
Genzyme Therapeutics Ltd.
Genzyme Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Genzyme Therapeutics Ltd. develops transformative therapies for patients affected by rare and debilitating diseases. Its treatment areas include thyroid cancer, sclerosis, Fabry disease and Pompe. The company was founded on November 5, 2001 and is headquartered in Oxford, the United Kingdom. | Health Technology |
